Primary Immunodeficiency Diseases Market: Key Insights
In response to the rising incidence of antibody diseases, Transparency Market Research (TMR) forecasts the global primary immunodeficiency market to surge at 6.1% CAGR between 2015 and 2023. Developed regions such as Europe and North America are predominantly contributing to the growth witnessed by this market. The consistent approval of novel therapeutic options for primary immunodeficiency diseases (PIDD) and extensive research and development investments by key players are likely to bolster opportunities for the market in the forthcoming years.
On the flip side, the absence of proper reimbursement and high cost of therapies will inhibit the market’s growth trajectory to an extent. Nevertheless, with favorable government policies and funding for research and development in biopharma and pharmaceuticals, growth prospects for the market seem quite promising.
TMR expects the global PIDD market to reach US$7.5 bn by the end of 2023, from a valuation of US$4.3 bn in 2014.
Demand for PIDD Treatment Highest in North America and Europe
Collectively accounting for a share of 79.4% in the global PIDD market, North America and Europe emerged as the dominant regional segments in 2014. Among these regions, North America boasted the largest share of 56.2% in 2014, with the U.S. at the fore. As per TMR, the U.S. held over 80.2% of the PIDD market in North America in the same year. The nation is expected to continue demonstrating lucrative opportunities for the PIDD market through the forecast period.
Over the last couple of years, a persistently increasing prevalence of diseases such as selective IgA deficiency, IgG subclass deficiency, and common variable immune deficiency has been witnessed in North America. This has fuelled the uptake of PIDD therapeutics. However, the growing awareness pertaining to side-effects such as renal failure and allergic reactions frequently associated with the treatment could hamper the market’s growth to an extent.
The primary immunodeficiency diseases market in North America, which stood at US$2.4 bn in 2014, is expected to reach US$4.3 bn by the end of 2023. The market is therefore expected to rise at a CAGR of 6.4% during the period.
In Europe, the market is expected to gain from the increasing awareness regarding PIDD and favorable government support. The presence of companies such as Baxter International Inc., CSL Behring LLC, and Blotest Pharmaceuticals Corporation also supports the market’s expansion in the region. Apart from this, emerging nations in Asia Pacific also exhibit lucrative scope for the expansion of the PIDD market. The increasing willingness among people to spend on novel therapeutics augurs well for sales prospects of the market in Asia Pacific. The region currently holds only a moderate share in the market. However, in the near future the opportunities for sale of PIDD therapeutics in the region will increase considerably.
Rising Uptake of Immunoglobulin (Ig) Replacement Therapy Expected in Near Future
By treatment, stem cell and gene therapy, antibiotic therapy, immunoglobulin (Ig) replacement therapy, and others make the key segments in the global PIDD market. Of these, immunoglobulin replacement has been in use for the treatment of chronic ailments for the past two decades. Due to the recent developments, it is also used for the treatment of partial antibody deficiency and combined immunodeficiencies. The segment therefore emerged dominant in the market in 2014. As per TMR, immunoglobulin replacement therapy will hold on to its position as the market leader through the forecast period.
Despite, Ig replacement therapy being the most widely accepted treatment among PIDD patients, the use of antibiotics as an adjunct therapy is poised to surge in the near future. Some of the most commonly used antibiotics include penicillin, macrolides, cephalosporins, fluoroquinolones, and tetracyclines.
The demand for stem cell and gene therapy is also expected to increase during the forecast period, which in turn will augment the demand for effective PIDD treatment.
Some of the most prominent companies in the global primary immunodeficiency diseases market are CSL Behring LLC, Baxter International, Inc., Grifols S.A., Octapharma AG, and others.
This report on the primary immunodeficiency diseases (PIDD) market studies the current as well as future prospects of the market. The stakeholders of this report include pharmaceuticals companies, diagnostic kits providers, distributors, care providers and insurance companies (payers) and other intermediaries engaged in PIDD as well as new entrants that are planning to enter in this segment. This report comprises an elaborate executive summary with a market snapshot providing overall information of various segments and sub-segments considered in the study scope. The executive summary also provides overall information and data analysis of the PIDD market with respect to the leading market segments based on Disease, Test, Treatment and Geography. The market revenue in terms of USD million for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments and sub-segments considered under the scope of study, considering 2014 as the base year. Pipeline analysis (qualitative) for Phase I, II candidates whereas a detailed quantitative aspect (US$ Mn) for III drugs are illustrated in the market overview chapter.
The report analyzed the PIDD market from four prominent segments: by Disease, by Test, by Treatment and by Geography. In terms of market by disease the overall market is segmented into three broad categories: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder. The antibody deficiency market is further analyzed and estimated for Agammaglobulinaemia, Common Variable Immune Deficiency, Selective IgA Deficiency, IgG Subclass Deficiency and Others. Whereas, cellular immunodeficiency market is sub-segmented into Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome, DiGeorge Syndrome and Others. The innate immune disorder market include Complement Deficiencies, Hyper IgE Syndrome and Others. Moreover this report also studies the global market by test for diagnosis which encompasses blood test and prenatal testing. The global PIDD market by treatment include both qualitative and quantitative analysis for immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy and others.
Geographically the market is divided into four major regions: North America, Europe, Asia Pacific and Rest of the World. The North America market incorporates The United States and Canada. The Europe region is accessed for Germany, United Kingdom and Rest of Europe. The Asia Pacific (APAC) market is sub-segmented into India, China and Rest of APAC. Rest of the World (RoW) include Latin America, Middle East and North Africa and Rest of RoW
Each of the aforementioned segments has been analyzed in detail for market trends, recent developments, outlook, and opportunities. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that currently have strong impact on the global PIDD market which could influence the market in the future as well. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition between leading market players in the U.S. market. Porter’s five forces analysis is also explained in this section to understand the market in U.S. considering different parameters that have an impact on the sustainability of the companies operating in the market.
The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their respective market shares across the globe. The recommendations section included in the report would assist existing market players in targeting the end users and stakeholders of PIDD and also to those aiming to seek an entry. The report also profiles major players in the PIDD market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.
The global primary immunodeficiency diseases market is segmented into the following categories:
Global Primary Immunodeficiency Diseases Market, by Disease
- Antibody Deficiency
- Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
- Common Variable Immune Deficiency
- Selective IgA Deficiency
- IgG Subclass Deficiency
- Cellular Immunodeficiency
- Ataxia Telangiectasia
- Hyper IgM Syndromes
- Wiskott-Aldrich Syndrome
- DiGeorge Syndrome
- Innate Immune Disorders
- Complement Deficiencies
- Hyper IgE Syndrome
Global Primary Immunodeficiency Diseases Market, by Test
- Blood Test
- Prenatal Testing
Global Primary Immunodeficiency Diseases Market, by Treatment
- Immunoglobulin Replacement Therapy
- Antibiotic Therapy
- Stem cell and Gene Therapy
Global Primary Immunodeficiency Diseases Market, by Geography
- North America
- Latin America
- Asia Pacific
- Rest of the World